Skip to main content

Free shipping for orders over 200 €.Products for research only.

Lyophilized research compound

Retatrutide GLP-3

In-vitro research reagent. Not for human or veterinary consumption.

Third-party testing · COAs availableDiscreet EU shippingCard, bank transfer or crypto (−5% on crypto)

Lyophilized peptide in sterile powder, pharmaceutical-grade glass vial. For in-vitro and preclinical research.

Reconstitution guide

Dosages, protocols and storage per peptide.

Vial format

5 mgout of stock10 mgout of stock20 mg

Reconstitution solvent

Bacteriostatic water · 10 ml USP

+15 €
1

Total

135 €

Limited stock on Retatrutide, GHK-CU, and MT-2 — for this SKU, availability may change quickly.

Shipping within 24–48h subject to availability.

COAs availablePurity > 98%Shipping 24–48hDiscreet packagingCard, bank transfer & crypto
Certificate of analysis (PDF)

This lyophilized peptide is intended for in-vitro and preclinical research. It is formulated to provide stability and purity suited to advanced research protocols. Not for direct human or veterinary consumption.

The Element Research peptides are selected for their long-term stability and compatibility with demanding research protocols. Lyophilization ensures optimal storage before reconstitution.

Mechanism of action

Triple action synergy

Retatrutide is the first molecule to activate 3 hormonal receptors simultaneously, whereas semaglutide activates only one.

GLP-1GLP-101

Appetite control

Slows gastric emptying, increases satiety and reduces food intake. Acts on brain hunger receptors (hypothalamus).

GLP-1R receptor

GIPGIP02

Insulin sensitivity

Optimizes post-prandial insulin response and promotes controlled lipid storage, complementing the GLP-1 axis on glycemia.

GIPR receptor

GlucagonGlucagon03

Energy expenditure

Stimulates hepatic lipolysis and thermogenesis. Increases resting energy expenditure, the key differentiator vs other GLP-1s.

GCGR receptor

Retatrutide activates all 3 simultaneously. Semaglutide (Ozempic) only activates GLP-1. Tirzepatide (Mounjaro) activates GLP-1 + GIP. Retatrutide is the only one to also activate the Glucagon receptor, the source of its superiority in energy expenditure.

This site uses technical cookies necessary for its operation. Learn more